A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Sponsor
QLT Inc.
Study ID
NCT00042315
Phase
PHASE3
Status
Terminated

Conditions

  • Stage IIIb Non-small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To determine whether tariquidar + first-line single agent vinorelbine chemotherapy in patients with Stage IIIb/IV NSCLC will, with an acceptable safety profile, significantly improve overall survival compared with placebo + vinorelbine. To compare the effects of tariquidar/vinorelbine with placebo/vinorelbine on tumor response, time to disease progression, performance status, symptom progression, and quality of life in patients with Stage IIIb/IV NSCLC.

Key Dates

First listed
Aug 1, 2002
Start date
Jun 30, 2002
Status verified
May 2012
Primary completion
Jun 30, 2003
Completion
Jun 30, 2003

Study Design

Enrollment
490 participants
Allocation
RANDOMIZED

Related Studies